Neoplasms

All Conditions

Rare Diseases

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Amino Acids

Epirubicin

Tyrosine Kinase Inhibitors

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Tyrosine

Arotinib hydrochloride capsule combined with epirubicin, 21 days as a treatment cycle

Placebo combined with epirubicin, 21 days as a treatment cycle

Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.

Anlotinib hydrochloride capsule

Epirubicin can inhibit the synthesis of DNA and RNA.

Placebo of Anlotinib hydrochloride capsule

Arotinib hydrochloride capsule placebo

Shanghai Niu, Bachelor

YUHONG ZHOU, Doctor

Xiaohui Niu, Bachelor

Wei Guo, Doctor

A multicenter, randomized, double-blind, parallel-controlled Phase III trial to evaluate the efficacy and safety of anotinib hydrochloride capsule combined with epirubicin hydrochloride versus placebo combined with epirubicin hydrochloride in first-line treatment of advanced soft tissue sarcoma

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

A Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Time from the first dose to the first documentation of progression disease (PD) or death from any cause, whichever occurs first

From randomization to the time of death from any cause

Time from the first dose to the first documentation of PD or death from any cause, whichever occurs first

The sum of percentage of participants with complete response rate and partial response rate

percentage of participants with complete response, partial response plus stable disease

the time from the date of first documentation of a CR or PR to the date of first documentation of tumor progression

Proportion of patients with tumor regression meeting surgical resection criteria in each group during the study period

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma	NCT05121350	Soft Tissue Sar...	Anlotinib hydro... Epirubicin Arotinib hydroc...	18 Years - 75 Years	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma	NCT05121350	Soft Tissue Sar...	Anlotinib hydro... Epirubicin Arotinib hydroc...	18 Years - 75 Years	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma	NCT05121350	Soft Tissue Sar...	Anlotinib hydro... Epirubicin Arotinib hydroc...	18 Years - 75 Years	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Spots Global Cancer Trial Database for arotinib hydrochloride capsule placebo